

NHLRC3 Rabbit pAb

Catalog # AP96512

Product Information

Application	WB, IHC-P, IHC-F, IF, E
Primary Accession	Q5JS37
Other Accession	Q5JS37
Host	Rabbit
Clonality	Polyclonal
Calculated MW	38283
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human NHLRC3
Epitope Specificity	101-200/347
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Contains 4 NHL repeats.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	NHLRC3 contains 4 NHL repeats. The function of the NHLRC3 protein remains unknown. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. The gene SLITRK1, which is associated with Tourette syndrome, is on chromosome 13. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections.

Additional Information

Gene ID	387921
Other Names	4833441N19; 8030451K01Rik; mKIAA4083; RGD1565414; NHLRC3_HUMAN; NHLRC3; NHLRC3_MOUSE; NHL repeat containing 3
Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	NHLRC3
Cellular Location	Secreted.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.